Document is current

Any future updates will be listed below

Adverse drug reaction to tremelimumab and durvalumab in hepatocellular carcinoma patients: an analysis of the food and drug administration adverse event reporting system database

Crossref DOI link: https://doi.org/10.1186/s12885-025-14696-7

Published Online: 2025-08-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark